Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: A minireview

Journal of Chemotherapy

Volumn 7, Issue 3, 1995, Pages 221-223

  Periti, P ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Brodimoprim; Co trimoxa zole; Dihydrofolate reductase inhibitors; Trimethoprim

Indexed keywords

BRODIMOPRIM; DIHYDROFOLATE REDUCTASE; TRIMETHOPRIM;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; IN VITRO STUDY; NONHUMAN; STEADY STATE;

ANTIBIOTICS; DRUG EVALUATION; FOLIC ACID ANTAGONISTS; HUMAN; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 0029038432     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.1995.7.3.221     Document Type: Article

References (22)

1. Hitchings, GH. The utilization of biochemical differences between host and parasite as a basis for chemotherapy. In: Goodwin LE, Nurino-Smith RH (Eds). Drugs, parasites, and hosts. Churchill, London, 1962: 196-210.
2. Brumfitt W, Hamilton-Miller JMT. Co-trimoxazole or trimetoprim alone? A viewpoint on their relative place in therapy. Drugs 1982; 24: 453-458.
3. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, 5.1.8. Sulphonamides and trimethoprim, Number 25 (March 1993), 1993: 227-228.
4. Reeves D. Good antimicrobial prescribing. Sulphonamides and trimetoprim. Lancet 1982; August 14: 370-373.
5. Kucers A, Bennett N McK, Kemp RJ. Trimethoprim, co-trimoxazole (Co-T) and other trimethoprim combinations. In: The use of antibiotics, Fourth ed., William Heinemann Medical Books, London, 1987: 1118-1202.
6. Braunsteiner AR, Fisinger F. Brodimoprim: therapeutic efficacy and safety in the treatment of bacterial infections. J Chemother 1993; 5: 153-157.
7. Brumfitt W, Hamilton-Miller JMT. Reassessment of the rationale for the combinations of sulfonamides with diaminopyrimidines. J Chemother 1993; 5: 111-120.
8. Sande MA, Kapusnik-Uner JE, Mandell GL. Antimicrobial agents; trimethoprim-sulfamethoxazole. In: The Pharmacological Basis of Therapeutics, eighth ed. (Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds), Pergamon Press, New York, 1990: 1054-1057.
9. Avery GS. Trimethoprim-sulphamethoxazole: a review. Drugs 1971; 1: 7-53.
10. Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J Infect Dis 1973; 128 (Suppl): 442-462.
11. Hitchings GH. Biochemical background of trimethoprim-sulfamethoxazole. Med J Australia 1973; 1 (Suppl): 5-9.
12. Wormser GP, Keusch GT, Hell RC. Co-trimoxazole (trimethoprim-sulfamethoxazole). An update review of its antibacterial activity and clinical efficacy. Drugs 1982; 24: 459-518.
13. Then RL, Hermann F. Properties of brodimoprim as an inhibitor of dihydrofolate reductase. Chemotherapy 1984; 30: 18-25.
14. Hartman PG. Molcular aspects and mechanism of action of dihydrofolate reductase inhibitors. J Chemother 1993; 5: 17-24.
15. Amyes SGB. Comparative antibacterial spectrum of trimethoprim and brodimoprim. J Chemother 1993: 5: 63-67.
16. Benoit-Lemercier C, Bergogne-Berezin E, Joly-Guillou ML. In vitro brodimoprim activity on bacterial strains. J Chemother 1993; 5: 81-92.
17. Amyes SGB, Towner KJ. Trimethoprim resistance: epidemiology and molecular aspects. J Med Microbiol 1990; 31: 1-19.
18. Goldstein FW, Acar JG. Epidemiology of resistance to diaminopyrimidines. J Chemother 1993; 5: 99-103.
19. Thomson CJ. Trimethoprim and brodimoprim resistance of Gram-positive and Gram-negative bacteria. J Chemother 1993; 5: 104-110.
20. Periti P, Mazzei T, Mini E, Novelli A. Brodimoprim, farmacologia clinica e chemioterapia. Farm Ter 1993; Suppl 1: 5-80.
21. Stephan-Guldner M. Preclinical toxicology and safety pharmacology of brodimoprim in comparison to trimetoprim and analogs. J Chemother 1993; 5: 48-57.
22. Salmi HA. Brodimoprim in acute respiratory tract infections. J Chemother 1993; 5: 532-536.